Literature DB >> 15666101

Malignant adenoma: diagnosis, staging, risk factors, lymph node involvement and problems of sampling.

M Risio1, R Fiocca.   

Abstract

Colorectal adenoma containing invasive carcinoma corresponds to a carcinoma invading the submucosa and represents the earliest form of clinically relevant colon cancer. Despite the generally favourable course after endoscopic removal, a limited risk of developing lymph node metastases still exists and the correct histologic assessment of malignant polyps can help in defining the evolutive potential. At present, histopathologic parameters alone determine whether a high (35%) or low (7%) risk of nodal metastases exists and the most relevant diagnostic criteria are the grade of differentiation of invasive adenocarcinoma, vascular invasion, the level of invasion of carcinomatous cells and the status of the resection margin.

Entities:  

Mesh:

Year:  2004        PMID: 15666101     DOI: 10.1007/s10151-004-0171-4

Source DB:  PubMed          Journal:  Tech Coloproctol        ISSN: 1123-6337            Impact factor:   3.781


  3 in total

1.  Colorectal Cancer OncoGuia: surgical pathology report guidelines.

Authors:  Xavier Sanjuán; Antonio Salas; Josep Lloreta; Paula Manchon Walsh
Journal:  Clin Transl Oncol       Date:  2010-03       Impact factor: 3.405

Review 2.  Clinical outcome of low- and high-risk malignant colorectal polyps: results of a population-based study and meta-analysis of the available literature.

Authors:  Carmela Di Gregorio; Luca Reggiani Bonetti; Carmela de Gaetani; Monica Pedroni; Shaniko Kaleci; Maurizio Ponz de Leon
Journal:  Intern Emerg Med       Date:  2012-03-27       Impact factor: 3.397

3.  Histological factors contributing to a high risk of recurrence of submucosal invasive cancer (pT1) of the colon and rectum after endoscopic therapy.

Authors:  Ichiro Nakada; Takanobu Tabuchi; Takeshi Nakachi; Jiro Shimazaki; Satoru Konishi; Motonobu Katano; Hideyuki Ubukata; Yoshihisa Goto; Yoshinori Watanabe; Takafumi Tabuchi
Journal:  Surg Today       Date:  2008-07-31       Impact factor: 2.549

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.